Hint mode is switched on Switch off

Xencor, ordinary share
XNCR, US98401F1057

Add a stock to WL
Choose all Reset all
Xencor, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Xencor, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Issuer
  • Full borrower / issuer name
    Xencor, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    XNCR
  • Placement
    03.12.2013
  • Lock up period
    180
  • Number of papers
    12,730,000
  • Volume of raised funds
    70.02 mln USD
  • Final placement price
    5.5 USD
  • Price change since placement date
    264.09%
  • By capitalization
    161.82 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    XNCR
  • Placement
    23.02.2015
  • Lock up period
    180
  • Number of papers
    5,500,000
  • Volume of raised funds
    82.83 mln USD
  • Placement share
    14.89%
  • Final placement price
    15.06 USD
  • Price change since placement date
    32.97%
  • By capitalization
    556.23 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    XNCR
  • Placement
    01.12.2016
  • Lock up period
    180
  • Number of papers
    4,585,000
  • Volume of raised funds
    110.04 mln USD
  • Placement share
    10.03%
  • Final placement price
    24 USD
  • Price change since placement date
    -16.56%
  • By capitalization
    1,097.37 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    XNCR
  • Placement
    19.03.2018
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    154.4 mln USD
  • Placement share
    9.61%
  • Final placement price
    30.88 USD
  • Price change since placement date
    -35.15%
  • By capitalization
    1,605.84 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Related Stock indices

Indicators

News

29/07/2026 Xencor: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
04/03/2026 Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
04/03/2026 Xencor: Termination Of A Material Definitive Agreement
18/09/2025 Barclays Initiates Xencor At Underweight, Sees Limited Upside From Pipeline
12/06/2025 Xencor: Submission Of Matters To A Vote Of Security Holders
All organization news

Holders

Industry Leaders

Registration is required to get access.